Dr. Zhigang Li, Ph.D. in Applied Chemistry from Dalian University of Technology. Deeply engaged in research work in the State Key Laboratory of Applied Chemistry, published several papers in renowned academic journals such as Bioorg. Med. Chem., Tetrahedron. Won Shanghai Science and Technology Development Funds (B) in 2011. Applied about 20 patents in China, the United States, the European Union and the World Intellectual Property Organization. He is currently the Scientific research Vice President of Medicilon’s chemistry department. Responsible for medicinal chemistry, synthetic chemistry and other chemistry projects in drug discovery phase. Accumulated many experiences in synthesis of heterocycles, nucleosides and carbohydrates. Has worked with many domestic and foreign pharmaceutical companies and helped to advance these projects from lead optimization to pre-clinic candidate confirmation. Among them, the anti –tumor candidate PRT543 based on PRMT5 has entered phase I clinic trial in US; the second brain penetration BRAF inhibitor ABM-1310 also entered phase I clinic trial in US.
Shanghai Medicilon Inc.
Address: No. 585, Chuanda Road, Pudong, Shanghai, 201200, China